GlaxoSmithKline Consumer Nigeria Plc (GSK) declared a gross profit of N10, 326, 243 for 2015, as against N10, 801, 472 in 2014.
Revenue from the sale of goods and services for 2015 was N30, 634, 708 a five percent increase to the N30, 521, 127revenue recorded in the previous year.
The profit before tax was N1,157, 514 and 2014 was N2,752, 216 while the profit for the year due to owners of the parent on 2015, N965, 047, while it was N1, 848, 842 in 2014.
Besides, the profit after tax for the year end was N965, 047, which is over 50 per cent decrease of the previous year’s N1, 848, 842.
The profit before tax was N358, 761m, which is 3.8 per cent less than 9per cent of the previous year of N717, 526.
The cash flows from operating activities for the Group in 2015 was N965, 047, N1, 848, 842 for 2014 and N956, 315 for the company in 2015 and N1, 830, 533 for 2014.
The group’s revenue for the year from continuing operations excluding investment income
The segment revenue for the year end was N30, 634, 707, as against N30, 521, 127 for the previous year just as the segment profit was N1, 740, 308, for year end and N3, 536, 129 for 2014.
The issued and fully paid share capital of the company N478, 350, 595 divided into 956, 701, 190 ordinary shares of 50 kobo
A total of 512, 635, 649 shares equivalent to 53.6 per cent are held by Nigerian shareholders, while 444, 065, 541 shares equivalent to 46.4 per cent are held by GSK Plc UK through its wholly owned subsidiaries, Setfirst Limited and SmithKlineBeecham Ltd as at 31 December, 2015. The share capital of the company was increased from N480m to N750m by the creation of 540m ordinary shares of 50kobo each to bring the total number of shares to 1.5bn ordinary shares of 50 kobo each.
The proposed dividend approved for shareholders as at 31 December 2015 was N356,761m as against the N717, 526m
